Amylyx gets first approval for ALS drug from Canada [Globe and Mail, The (Toronto, Canada)]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Globe and Mail, The
Log in or create a free account to listen to this article. Canada has approved Amylyx Pharmaceuticals' treatment for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, the drugmaker said on Monday, the first such approval for the oral drug. The decision came with certain conditions, including the release of data from its global late-stage study of about 600 patients, which is expected in 2024, as well as additional studies. The approval for the drug, which will be sold in Canada under the brand Albrioza, is based on a mid-stage study in 137 patients and a long-term follow-up phase, which showed it slowed a decline in physical functioning among patients. ALS, whose cause is largely unknown, causes nerve cells in the brain and spinal cord to break down, affecting physical function and resulting in severe disability and death. About 3,000 Canadians are currently living with ALS, with the average life expectancy from the symptom onset being two to five years, acc
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), Cassava Sciences, Inc. (NASDAQ:SAVA), GrafTech International Ltd. (NYSE:EAF), and Mobileye Global Inc. (NASDAQ:MBLY)Accesswire
- Investigation Alert Amylyx, Hut 8, Xponential Fitness, and iRhythm Technologies: Submit Your Information Now to Johnson Fistel, LLPGlobeNewswire
- The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) had its price target lowered by analysts at Robert W. Baird from $4.00 to $3.00. They now have a "neutral" rating on the stock.MarketBeat
- Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 2/22/24 - Miss
AMLX
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- AMLX's page on the SEC website